Oral Administration of Resveratrol-Loaded Solid Lipid Nanoparticle Improves Insulin Resistance Through Targeting Expression of SNARE Proteins in Adipose and Muscle Tissue in Rats with Type 2 Diabetes

Table 2 The effect of RES and SLN-RES treatment on the body weight gain, fasting blood sugar, insulin, and HOMA index in diabetic rat models

Group	DC	DC + RES	DC + SLN-RES
Body weight (g)	− 69.4 ± 14.4	− 49.9 ± 18.0^α+	− 12.3 ± 2.8^α#π
FBS (mg/dl)	+ 211.3 ± 92.1	+ 98.3 ± 38.6^α*	+ 38.5 ± 13.6^α#δ
Insulin (μU/ml)	− 4.0 ± 1.2	− 1.8 ± 0.9^α#π	− 0.9 ± 0.2^α#π
HOMA	+ 3.0 ± 1.1	+ 2.2 ± 0.8^α#	+ 0.1 ± 0.04^α#πδ

The alteration of parameters was expressed as compared with healthy control group. DC diabetic control, RES resveratrol treatment 10 mg/kg, SLN-RES resveratrol-loaded solid lipid nanoparticles containing 10 mg/kg of resveratrol, FBS fasting blood sugar, HOMA homeostasis model assessment-estimated insulin resistance. Data were expressed as mean ± SD
^αCompared to the DC group
^δThere was a significant difference between RES and SLN-RES group (p < 0.05)
^πRestored to the HC group (there was no significant difference compared to the HC group (p > 0.05)).
*p < 0.05
⁺p < 0.01
^#p < 0.001